Sanati Mehdi, Figueroa-Espada Christian G, Han Emily L, Mitchell Michael J, Yavari Saber Amin
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand 97178, Iran.
Department of Bioengineering, University of Pennsylvania, 210 South 33rd Street, Philadelphia, Pennsylvania 19104, United States.
ACS Nano. 2024 Dec 24;18(51):34425-34463. doi: 10.1021/acsnano.4c11259. Epub 2024 Dec 12.
Chemoresistance remains a long-standing challenge after cancer treatment. Over the last two decades, RNA interference (RNAi) has emerged as a gene therapy modality to sensitize cancer cells to chemotherapy. However, the use of RNAi, specifically small-interfering RNA (siRNA), is hindered by biological barriers that limit its intracellular delivery. Nanoparticles can overcome these barriers by protecting siRNA in physiological environments and facilitating its delivery to cancer cells. In this review, we discuss the development of nanomaterials for siRNA delivery in cancer therapy, current challenges, and future perspectives for their implementation to overcome cancer chemoresistance.
化疗耐药仍然是癌症治疗后长期存在的挑战。在过去二十年中，RNA干扰（RNAi）已成为一种基因治疗方式，可使癌细胞对化疗敏感。然而，RNAi的使用，特别是小干扰RNA（siRNA），受到限制其细胞内递送的生物屏障的阻碍。纳米颗粒可以通过在生理环境中保护siRNA并促进其递送至癌细胞来克服这些屏障。在本综述中，我们讨论了用于癌症治疗中siRNA递送的纳米材料的发展、当前挑战以及将其用于克服癌症化疗耐药的未来前景。
